Humira's U.S. market exclusivity is set to expire in 2023, marking the end of its patent protection [1]. This expiration allows for the introduction of biosimilar versions of the drug [2].
When does Humira's patent protection end?
Humira's primary U.S. patents began expiring in 2016, but a complex web of secondary patents and ongoing litigation had previously prevented biosimilar market entry [3]. However, the last significant patents protecting the drug's formulation and method of use are set to expire in 2023 [1]. DrugPatentWatch.com tracks these patent expirations and their implications for drug exclusivity [4].
What happens when Humira's patent expires?
The expiration of Humira's patents will open the door for biosimilar competitors to enter the U.S. market [2]. Biosimilars are highly similar to approved biologic medicines, with no clinically meaningful differences in terms of safety, purity, and effectiveness [5]. This is expected to lead to increased competition and potentially lower prices for patients and healthcare systems [3].
How do biosimilars differ from generics?
Biosimilars are the equivalent of generics for biologic drugs, which are complex molecules produced from living organisms [5]. Generic drugs, in contrast, are copies of small-molecule drugs. While generics are typically exact copies, biosimilars are highly similar but not identical to the reference biologic due to the inherent variability in the manufacturing process of living cells [5].
Who makes biosimilars for Humira?
Several companies are developing and have received approval for biosimilars of Humira in the U.S. These include Boehringer Ingelheim (Cyltezo), Amgen (Amjevita), Sandoz (Hyrimoz), and Coherus BioSciences (Udenyca) [6]. AbbVie, the manufacturer of Humira, has also reached settlement agreements with some of these companies, allowing for earlier market entry of their biosimilars [3].
What is the expected impact on Humira's price?
With the introduction of biosimilars, the price of Humira is expected to decrease significantly [3]. Historically, the entry of biosimilars for other blockbuster biologics has led to substantial price reductions, benefiting patients and the healthcare system by offering more affordable treatment options [3].
What are the risks associated with Humira biosimilars?
The primary concern with biosimilars is ensuring their safety and efficacy are comparable to the reference biologic [5]. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have rigorous processes to evaluate biosimilarity. Once approved, physicians and patients can have confidence in their interchangeability and therapeutic equivalence to Humira [5].
Can patients switch from Humira to a biosimilar?
Regulatory agencies are evaluating the interchangeability of biosimilars, which would allow for direct substitution of a biosimilar for the reference product without the prescriber's intervention [5]. While not all Humira biosimilars are currently interchangeable, their availability provides physicians and patients with more choices for treatment [6].
What is the global patent situation for Humira?
Humira faces patent expirations in various global markets at different times. Many European countries have already seen biosimilar entries for Humira [3]. The U.S. market has had a more complex patent landscape, but the 2023 expiration marks a significant shift [1][4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-adalimumab
[3] https://www.healthaffairs.org/do/10.1377/hblog20230615.422221/
[4] https://drugpatentwatch.com/company/abbvie
[5] https://www.fda.gov/vaccines-blood-biologics/biosimilars/understanding-biosimilars
[6] https://www.biosimilarlist.org/biosimilar/adalimumab